TABLE 5.
Median patient prices and affordability of insulin and comparator medicines in the private sector.
| Medicine | Strength | No. of units needed for monthly treatment | Median unit price (in Pak rupees) | Days’ wages for monthly treatment | ||
|---|---|---|---|---|---|---|
| Originator | Generic | Originator | Generic | |||
| Human insulin | ||||||
| Short-acting human | 100 U/ml | 10 ml | 868.9 | 610.0 | 1.4 | 1.0 |
| Intermediate-acting human | 100 IU/ml | 10 ml | 819.0 | 605.0 | 1.3 | 1.0 |
| Mixed human | 100 IU/ml | 10 ml | 888.3 | 649.0 | 1.5 | 1.1 |
| Analog insulin | ||||||
| Rapid-acting analog | 100 IU/ml | 10 ml | 2838.6 | - | 4.7 | - |
| Long-acting analog | 100 IU/ml | 10 ml | 3120.0 | 3000.0 | 5.2 | 5.1 |
| Mixed analog | 100 IU/ml | 10 ml | 2868.6 | - | 4.8 | - |
| Comparator medicines | ||||||
| Atorvastatin | 20 mg | 30 tab | 112.8 | 23.8 | 5.7 | 1.2 |
| Bisoprolol | 5 mg | 60 tab | 16.7 | 7.2 | 1.6 | 0.7 |
| Glibenclamide | 5 mg | 90 tab | 2.1 | 1.0 | 0.3 | 0.1 |
| Gliclazide | 80 mg | 60 tab | 9.3 | 6.0 | 0.9 | 0.6 |
| Metformin | 500 mg | 90 tab | 1.9 | 1.6 | 0.3 | 0.2 |